The 2011 start-up Arteaus Therapeutics LLC, funded by Atlas Venture and OrbiMed, has generated a return more than 16 times the original $18m the venture capital firms invested in the company now that royalties from the Eli Lilly & Co. migraine therapy Emgality (galcanezumab) have been sold to Royalty Pharma for $260m.
Arteaus was established with a $18m Series A funding round to develop the Lilly-discovered calcitonin gene-related peptide (CGRP) inhibitor galcanezumab...






